08:58 AM EDT, 10/15/2026 (MT Newswires) -- BofA Global Research reiterated its rating on Roche (RO.SW), highlighting its optimistic view on the Swiss pharmaceutical giant's investigational breast cancer drug giredestrant. "Our bullish view on a giredestrant lidERA launch end-26E remains core to our Buy thesis and likely also explains a large part of Roche's share price strength since mid-year (in addition to lack of binary event risk relative to other names in the sector). Cons assumes cCHF6.5bn risk-adjusted 33E sales for giredestrant, with us above at cCHF8bn peak, and buyside expectations similar. Any competitive risk is therefore important, particularly given ROP is currently perceived as a non-binary growth hiding place in the sector by many generalist investors," analysts said Thursday. "Overall, while positive competitor switch data may pose a risk to sentiment, we see limited impact to our gire peak sales, given we think both upfront and switch strategies can co-exist. The research firm also noted the drugmaker's busy pipeline over the next two years, including a potential launch of divarasib in second-line lung cancer and approval of multiple sclerosis treatment fenebrutinib in 2027. The stock's price objective stands at 415 francs.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.